My Cancer Genome: Genetically Informed Cancer Medicine

  • Home
  • DIRECT
  • About Us
  • Myelodysplastic Syndromes
  • ASXL1
    • ASXL1 Mutations
  • BCOR
    • BCOR Mutations
  • DNMT3A
    • DNMT3A Mutations
  • ETV6
    • ETV6 Mutations
  • EZH2
    • EZH2 Mutations
  • NF1
    • NF1 Mutations
  • RUNX1
    • RUNX1 Mutations
  • SF3B1
    • SF3B1 Mutations
  • SRSF2
    • SRSF2 Mutations
  • STAG2
    • STAG2 Mutations
  • TET2
    • TET2 Mutations
  • TP53
    • TP53 Mutations
  • U2AF1
    • U2AF1 Mutations
  • ZRSR2
    • ZRSR2 Mutations
  • Other Diseases
    • Acute Lymphoblastic Leukemia
    • Acute Myeloid Leukemia
    • Anaplastic Large Cell Lymphoma
    • Basal Cell Carcinoma
    • Bladder Cancer
    • Breast Cancer
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
    • Colorectal Cancer
    • GIST
    • Gastric Cancer
    • Glioma
    • Inflammatory Myofibroblastic Tumor
    • Lung Cancer
    • Medulloblastoma
    • Melanoma
    • Myeloproliferative Neoplasms
    • Neuroblastoma
    • Ovarian Cancer
    • Prostate Cancer
    • Rhabdomyosarcoma
    • Thymic Carcinoma
    • Thyroid Cancer
    • Waldenstrom Macroglobulinemia
  • Molecular Medicine
    • Anticancer Agents
    • Circulating Tumor DNA
    • Detecting Gene Alterations in Cancers
    • Immunotherapy in Cancer
    • Overview of Targeted Therapies for Cancer
    • Pathways
    • Types of Molecular Tumor Testing
  • Take Our Survey
  • Glossary
  • News
  • Our Team
  • Acknowledgements
  • What is ZRSR2?
  • ZRSR2 in Myelodysplastic Syndromes
  • Clinical Trials

ZRSR2

Zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 (ZRSR2) is a gene that encodes for a member of the spliceosome. The protein coded by this gene associates with the U2 auxiliary factor, which plays an important role in RNA splicing (Gene 2014). Spliceosome mutations are observed in MDS, chronic lymphocytic leukemia (CLL), AML, and chronic myelomonocytic leukemia (CMML), and these mutations can cause abnormal expression patterns of some genes involved in cancer pathogenesis (Chesnais et al. 2012).​

Related Pathways

  • RNA splicing

Contributors: Stephen A. Strickland, M.D., MSCI, Annette S. Kim, M.D., Ph.D.

Suggested Citation: Strickland, S., A. Kim. 2015. ZRSR2. My Cancer Genome https://www.mycancergenome.org/content/disease/myelodysplastic-syndromes/zrsr2/?tab=0 (Updated December 7).

Last Updated: December 7, 2015

ZRSR2 in Myelodysplastic Syndromes

ZRSR2 mutations occur in 6.8% of MDS (COSMIC). The role of ZRSR2 mutations in MDS is not yet well understood (Cazzola, Della Porta, and Malcovati 2013). Unlike many of the other spliceosome genes, mutations in ZRSR2 are found throughout the gene without recurrent sites of mutations.

ZRSR2 mutations have been associated with neutral or unfavorable outcomes. Thol et al. (2012) observed no impact of ZRSR2 mutations on outcomes of 193 MDS patients, while Damm et al. (2012) observed shorter overall survival and higher likelihood of transformation to AML for patients with ZRSR2 mutations and no mutation in TET2 in a study of 221 MDS patients.​

Contributors: Stephen A. Strickland, M.D., MSCI, Annette S. Kim, M.D., Ph.D.

Suggested Citation: Strickland, S., A. Kim. 2015. ZRSR2 in Myelodysplastic Syndromes. My Cancer Genome https://www.mycancergenome.org/content/disease/myelodysplastic-syndromes/zrsr2/ (Updated October 16).

Last Updated: October 16, 2015

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.mycancergenome.org to check it out!

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.

  • MCG Home |
  • About Us |
  • Acknowledgments |
  • Give |
  • Site Map |
  • Legal |
  • APIs and Licensing
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center   Copyright © 2010 - 2019 MY CANCER GENOME